CorVel (NASDAQ:CRVL) Stock Price Passes Below 200-Day Moving Average – What’s Next?

CorVel Corp. (NASDAQ:CRVL) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $60.51 and traded as low as $59.81. CorVel shares last traded at $59.88, with a volume of 153,628 shares traded.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Weiss Ratings downgraded CorVel from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, April 6th. Wall Street Zen raised CorVel from a “hold” rating to a “buy” rating in a report on Saturday, May 30th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

CorVel Trading Up 0.0%

The firm has a market capitalization of $3.04 billion, a price-to-earnings ratio of 27.98 and a beta of 0.99. The firm has a fifty day moving average price of $57.44 and a 200 day moving average price of $60.51.

CorVel (NASDAQ:CRVL) last announced its earnings results on Tuesday, May 19th. The business services provider reported $0.61 EPS for the quarter. The business had revenue of $248.55 million for the quarter. CorVel had a return on equity of 29.92% and a net margin of 11.51%.

Insiders Place Their Bets

In other CorVel news, VP Jennifer Yoss sold 1,999 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $61.02, for a total value of $121,978.98. Following the transaction, the vice president directly owned 2,173 shares in the company, valued at approximately $132,596.46. This trade represents a 47.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Maxim Shishin sold 2,400 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $54.00, for a total value of $129,600.00. Following the completion of the transaction, the insider owned 7,050 shares in the company, valued at $380,700. The trade was a 25.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 44.56% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in CorVel by 1.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,287,788 shares of the business services provider’s stock valued at $254,541,000 after buying an additional 45,071 shares during the last quarter. State Street Corp boosted its position in CorVel by 2.7% in the 4th quarter. State Street Corp now owns 1,179,572 shares of the business services provider’s stock valued at $79,822,000 after buying an additional 30,987 shares during the last quarter. Geode Capital Management LLC boosted its position in CorVel by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 927,845 shares of the business services provider’s stock valued at $62,796,000 after buying an additional 28,666 shares during the last quarter. Norges Bank bought a new position in CorVel in the 4th quarter valued at $29,250,000. Finally, Qube Research & Technologies Ltd boosted its position in CorVel by 100.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 236,713 shares of the business services provider’s stock valued at $18,326,000 after buying an additional 118,879 shares during the last quarter. 51.36% of the stock is currently owned by institutional investors.

About CorVel

CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.

The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).